Earnings

Adobe shares soar 15% on better-than-expected results

Products You May Like

In this article

Shantanu Narayen, CEO of Adobe being interviewed by Jim Cramer
Linda Dimyan | CNBC

Adobe shares jumped 15% in extended trading on Thursday after the design software maker reported earnings and revenue that topped estimates.

Here’s how the company did in comparison with LSEG consensus:

  • Earnings per share: $4.48 adjusted, vs. $4.39 expected
  • Revenue: $5.31 billion vs. $5.29 billion expected

Adobe’s revenue grew 10% year over year in the quarter, which ended on May 31, according to a statement.

The company called for adjusted earnings per share of $4.50 to $4.55 for the fiscal third quarter, with $5.33 billion to $5.38 billion in revenue. Analysts polled by LSEG were looking for $4.48 in adjusted earnings per share and $5.4 billion in revenue.

Adobe bumped up its full-year view, calling for full-year adjusted earnings per share between $18.00 and $18.20 and revenue of $21.40 billion to $21.50 billion. Analysts surveyed by LSEG had projected $18.02 per share in adjusted earnings and $21.46 billion in revenue. The forecast in March was $17.60 to $18.00 in adjusted earnings per share, with $21.30 billion to $21.50 billion in revenue.

In recent weeks software peers SentinelOne, UiPath, Veeva have reduced their full-year revenue guidance citing economic weakness and corporate interest in artificial intelligence development.

Before Adobe issued the statement, shares were down 23% so far this year, while the S&P 500 index was up around 14%.

Executives will discuss the results with analysts on a conference call starting at 5 p.m. ET.

This is breaking news. Please check back for updates.

Products You May Like

Articles You May Like

U.S. sues Walmart, Branch Messenger over payment accounts for delivery drivers
How much money does Mariah Carey make from ‘All I Want For Christmas Is You’? ‘It’s a lot,’ music expert says
CBO and JCT Preview Economic Analysis of Extending TCJA
Tax Deductions for Non-Business Bad Debts
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

Leave a Reply

Your email address will not be published. Required fields are marked *